STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma

Signal Transducer and Activator of Transcription-3, Inflammation, and Cancer

(2009) Bharat B. Aggarwal et al.   Annals of the New York Academy of Sciences

Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness

(2009) J S Thompson Coon et al.   BRITISH JOURNAL OF CANCER

Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma

(2009) V Bilim et al.   BRITISH JOURNAL OF CANCER

Activated extracellular signal-regulated kinase is an independent prognostic factor in clinically confined renal cell carcinoma

(2009) Lee Campbell et al.   CANCER

Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

(2009) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

STAT3 as a target for inducing apoptosis in solid and hematological tumors

(2008) Khandaker Al Zaid Siddiquee et al.   CELL RESEARCH

WP1066, a Novel JAK2 Inhibitor, Suppresses Proliferation and Induces Apoptosis in Erythroid Human Cells Carrying the JAK2 V617F Mutation

(2008) S. Verstovsek et al.   CLINICAL CANCER RESEARCH

A Novel Inhibitor of Signal Transducers And Activators Of Transcription 3 Activation Is Efficacious Against Established Central Nervous System Melanoma and Inhibits Regulatory T Cells

(2008) L.-Y. Kong et al.   CLINICAL CANCER RESEARCH